Drugs / [F-18]SDM8
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04634994 | May 2025 → Dec 2026 expected | multiple sclerosis | Brigham and Women's Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [F-18]SDM8 | “Aim 1: To compare the cortical and subcortical grey matter synaptic density in PMS patients, patients with relapsing-remitting MS (RRMS), and healthy subjects, using a novel...” NCT04634994 ↗ |
| Known as | [F-18]SynvesT-1 | “Aim 1: To compare the cortical and subcortical grey matter synaptic density in PMS patients, patients with relapsing-remitting MS (RRMS), and healthy subjects, using a novel...” NCT04634994 ↗ |
| Modality | Diagnostic / imaging agent | “PET radiopharmaceutical.” NCT04634994 ↗ |
| Route | Intravenous | “an intravenous (IV) catheter will be inserted into the radial antecubital or other arm or hand vein for injection of tracer” NCT04634994 ↗ |